Exercise on microRNA in Osteoarthritis

June 2, 2023 updated by: Saglik Bilimleri Universitesi

Investigation Into the Effects of Exercise on microRNA Expressions in Patients With Knee Osteoarthritis

The present study is a prospective cohort study. This study will be conducted to determine the change in miRNA levels with exercise in knee Osteoarthritis (OA) patients. The main questions that the study aims to answer are:

Question 1: Does exercise therapy affect microrna expressions in patients with knee osteoarthritis?

Question 2: Does exercise therapy affect quality of life, pain, functional status and depression level in patients with knee osteoarthritis?

Participants; demographic information such as age, height, weight will be questioned. Exercises will performed twice a week under supervision and once a week as home program for eight weeks. Before and after exercise treatment, peripheral venous blood samples will taken from both groups. miRNA-146a, miRNA-155, miRNA-221-3p and miRNA-145 gene expressions will studied with the real-time PCR (polymerase chain reaction) method. miRNA-146a, miRNA-155, and miRNA-221-3p, miRNA-145 gene expressions will studied with the Real-time PCR method. The pain will evaluated with the Numeric Rating Scale (NRS), functional status with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), depression level with the Beck Depression Inventory (BDI), and quality of life with Short Form-36 (SF-36).

Study Overview

Detailed Description

Osteoarthritis is a degenerative disease causing joint pain, stiffness, and limitation of motion with loss of cartilage, osteophyte development, subchondral sclerosis, changes in the joint capsule and synovial membrane as a result of the disruption of genetic, biomechanical, and biochemical balances. Pharmacological treatments of osteoarthritis include simple analgesics, non-steroidal anti-inflammatory drugs, opioids and topical analgesics. Patient education, self-management programs, exercise, weight loss, assistive devices and lifestyle changes are non-pharmacological treatment methods.Exercise is one of the basic elements of the treatment modality. The purpose of the exercise; to relieve symptoms and improve muscle strength around joints. It is aimed to increase the quality of life with the adaptation of individuals to exercise.

miRNA, one of the small non-coding RNA subunits, is responsible for the modulation of protein-coding genes as a result of post-transcriptional repression. miRNA play an active role in many biological events such as cellular differentiation, apoptosis, proliferation, erythropoiesis, fibrosis and angiogenesis. Due to the role of miRNAs in normal development and diseases, it is thought that they will be a new biomarker for therapeutic purposes in the future. It was found that miRNAs play a key role in physiological conditions e.g. skeletal muscle hypertrophy, mitochondrial biogenesis, vascular angiogenesis, and metabolic events when combined with exercise. The identification of miRNAs that change in circulation with exercise is important in terms of providing new data on the physiological adaptation of exercise. In recent years, a large number of miRNAs have been identified in osteoarthritic tissues, which is important in terms of the regulation of gene expressions related to the pathogenesis of OA. OA-specific miRNA expressions is necessary for early diagnosis and treatment of OA as well as for monitoring the progression of the disease. It has been reported that miRNA-146a is intensely expressed in OA tissue and its expression is induced by inflammatory cytokines. MiRNA-145 is associated with chondrocyte homeostasis and is thought to be involved in the degradation of the extracellular matrix. MiRNA-155 is a miRNA that has a role in the development and regulation of innate and acquired immunity, and its expression is increased in tissues with OA compared to healthy tissue. It has an important role in hematopoiesis. MiRNA-221-3p was found to be associated with chondrocyte proliferation, gene expression, matrix degradation and apoptosis.

In this study it was aimed to determine the changes in miRNA levels of knee OA patients with exercise.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey
        • Bakırköy Dr. Sadi Konuk Training and Hospital Research Hospital, Physical Medicine and Rehabilitation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Having Kellgren-Lawrence grade 2 or grade 3 knee OA
  • Body mass index (BMI) between 20-35.

Exclusion Criteria:

  • Rheumatoid Arthritis,
  • Having knee replacement surgery,
  • Intra-articular injection in the last six months,
  • Usage of opioid analgesics or corticosteroids,
  • Being under severe pain (VAS>7),
  • Pregnancy,
  • Having cardiovascular disease,
  • Stroke and chronic obstructive pulmonary disease (COPD).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exercise Group
A total of 30 knee OA patients and 30 age/sex-matched healthy volunteers were included in the exercise and control groups. Exercises were performed twice a week under supervision and once a week as home program for eight weeks. Before and after exercise treatment, peripheral venous blood samples were taken from both groups. miRNA-146a, miRNA-155, miRNA-221-3p and miRNA-145 gene expressions were studied with the Real-time PCR method. miRNA-146a, miRNA-155, and miRNA-221-3p, miRNA-145 gene expressions were studied with the Real-time PCR method. The pain was evaluated with the Numeric Rating Scale (NRS), functional status with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), depression level with the Beck Depression Inventory (BDI), and quality of life with Short Form-36 (SF-36).
All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.
The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post-Treatment Gene Expressions of microRNA for Treatment Group
Time Frame: Through study completion, an average of 2 months.
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
Through study completion, an average of 2 months.
Gene Expressions of microRNA for Healthy Control Group
Time Frame: Baseline
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
Baseline
Pre-Treatment Gene Expressions of microRNA for Treatment Group
Time Frame: Baseline
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
Baseline
Pre-Treatment Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for Treatment Group
Time Frame: Baseline

WOMAC was used to evaluate functional status. There are a total of 24 questions on pain, morning stiffness and physical function.

0 points means 'not at all', 1 point means 'mild', 2 points 'moderate', 3 points 'severe', 4 points 'very severe'.

The total score is between 0 and 100, and a low score means that the individual is in good health.

Baseline
Post-Treatment Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for Treatment Group
Time Frame: At the beginning of the intervention and through study completion, an average of 2 month

WOMAC was used to evaluate functional status. There are a total of 24 questions on pain, morning stiffness and physical function.

0 points means 'not at all', 1 point means 'mild', 2 points 'moderate', 3 points 'severe', 4 points 'very severe'.

The total score is between 0 and 100, and a low score means that the individual is in good health.

At the beginning of the intervention and through study completion, an average of 2 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Short Form-36 (SF-36)
Time Frame: At the beginning of the intervention and through study completion, an average of 2 month
SF-36 was used to evaluate quality of life. This questionnaire consists of eight subsections. Scoring is made between 0-100 for each of the subsections. Higher scores indicate better function and well-being.
At the beginning of the intervention and through study completion, an average of 2 month
Beck Depression Inventory (BDI)
Time Frame: At the beginning of the intervention and through study completion, an average of 2 month

BDI was used to evaluate depression level. The test consists of 20 questions and each question includes 0, 1, 2, 3 points.

takes. At the end of the test; The scores marked by the patient for each question are summed up and the depression status is evaluated according to the score. The higher the score, the higher the level of depression.

At the beginning of the intervention and through study completion, an average of 2 month
Numeric Rating Scale (NRS)
Time Frame: At the beginning of the intervention and through study completion, an average of 2 month
NRS was used to pain level. A score of 0 means 'no pain' and a score of 10 means 'unbearable pain'.
At the beginning of the intervention and through study completion, an average of 2 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Fulya Senem KARAAHMETOĞLU, M.Sc, Saglik Bilimleri Universitesi
  • Study Chair: Zeynep Betül ÖZCAN, M.Sc, Saglik Bilimleri Universitesi
  • Study Chair: Meltem VURAL, Prof. Dr., Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospita
  • Study Chair: Işıl ÜSTÜN, Dr., Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospita
  • Study Chair: Alev KURAL, Prof. Dr., Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospita
  • Study Chair: Sibel KURAŞ, M. Sc., Saglik Bilimleri Universitesi
  • Study Chair: Bekir ERDOĞAN, M.Sc, Saglik Bilimleri Universitesi
  • Study Director: Halime Hanım PENÇE, Assoc. Prof., Saglik Bilimleri Universitesi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2018

Primary Completion (Actual)

September 11, 2019

Study Completion (Actual)

June 17, 2020

Study Registration Dates

First Submitted

May 6, 2023

First Submitted That Met QC Criteria

May 16, 2023

First Posted (Actual)

May 22, 2023

Study Record Updates

Last Update Posted (Actual)

June 6, 2023

Last Update Submitted That Met QC Criteria

June 2, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Exercise Programme

Subscribe